EGM
APRE icon

Engineers Gate Manager’s Aprea Therapeutics APRE Stock Holding History

Engineers Gate Manager’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-670
Closed -$38K – 1832
2021
Q4 		$38K Buy
+670
New +$59.2K ﹤0.01% 1901

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Engineers Gate Manager's APRE Position: Q1 2022 in Review

Engineers Gate Manager sold out of Aprea Therapeutics (APRE) in Q1 2022, closing a stake of 670 shares — an estimated $38K sold.

Engineers Gate Manager first reported a position in APRE in Q4 2021 and held it in 1 quarter. The position peaked at $38K in Q4 2021. 40 funds tracked by Wall St. Rank hold APRE as of Q1 2022.

  • Engineers Gate Manager reported no remaining Aprea Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Engineers Gate Manager sold 670 Aprea Therapeutics shares in Q1 2022, an estimated $38K.
  • Engineers Gate Manager first reported a position in Aprea Therapeutics in Q4 2021 and held it in 1 quarter.
  • Engineers Gate Manager's Aprea Therapeutics position peaked at $38K in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2022.

Based on Engineers Gate Manager's 13F filing for Q1 2022, filed 16 May 2022.